Endocrine Abstracts

Aim: To study the effect of testosterone replacement treatment in the aging male with T2DM.

Material and methods: Twenty-six hypogonadal men with T2DM and late-onset hypogonadism between the age 50–65 years (55.00 (50.00; 58.00)) were treated with a 1% testosterone gel within 12 months.

Results: Testosterone levels increased from 4.65 (2.70; 6.10) nmol/l at baseline to 13.65 (12.60; 15.20) nmol/l after 48 weeks of treatment (P<0.001). Free testosterone increased from 0.106 (0.062; 0.152) nmol/l to 0.426 (0.345; 0.553) nmol/l (P<0.001). SHBG decreased from 43.75 (31.83; 48.48) nmol/l to 30.40 (26.28; 32.03) nmol/l (P<0.001). We showed reduction of levels of TG from 2.09 (1.37; 3.42) mmol/l to 1.33 (1.12; 1.62) mmol/l (P=0.002), HbA1C from 8 (6.93; 10.68) to 6.8 (5.90; 8.15)% (P<0.05), leptin from 10.0 (4.0; 22.7) μg/l to 5.25 (4.03; 8.23) μg/l, HOMA-IR from 4.37 (1.98; 5.76) to 2.46 (1.98; 3.04). PSA levels fluctuated minimally within in the normal range. All patients reported improved mood, sexual function and QoL.

Conclusions: Treatment with the 1% testosterone gel was associated with significant improvements in the testosterone, triglyceride, HbA1C, leptin, HOMA-IR levels in men with late-onset hypogonadism and T2DM.

Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.

Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.